display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - HR positivebreast cancer - triple negativebreast cancer HER 2 negative
la/mBC - HR positivela/mBC - TNBC - L1 - all populationla/mBC - TNBC - L1 - PDL1 positivela/mBC - TNBC - L2 - all populationla/mBC - TNBC - L2 - PDL1 positivees-BC - TNBC - NA - all populationes-BC - HER2 negative - (neo)adjuvant (NA)
pembrolizumab based treatment
pembrolizumab alone NCT03051659 KEYNOTE-119 ... KEYNOTE-119 PD-L1 positive ... KEYNOTE-119 ... KEYNOTE-119 ... KEYNOTE-119 PD-L1 positive ... KEYNOTE-522
pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide I-SPY2
pembrolizumab plus SoC KEYNOTE-355 ... KEYNOTE-355 ... KEYNOTE-355 ...

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons